13 completed, 6 active not recruiting, 5 unknown, 3 recruiting. 15 Phase 2, 5 Phase 1, 4 Phase 3, 1 Early Phase 1, 1 Phase 4.
Follow this drug Literature Review of Radium-223 trials Research Report on Radium-223
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer Ra223, Darolutamide Oral Tablet, Androgen Deprivation Therapy (ADT) - Metastatic Hormone-Sensitive Prostate Cance | Phase 2 | Not yet recruiting | Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD | 50 | 2026-09-01 | 2026-07-21 |
| AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | AstraZeneca | 670 | 2026-05-04 | 2026-10-19 |
| SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization Radium-223, 177Lu-DOTATATE, 177Lu-PSMA-617 - Prostate Cancer, Advanced Cancer | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 80 | 2025-02-03 | 2026-03-30 | |
| Efficacy of Ra-223 in PSMA PET Optimally Selected Patients Radium-223, PSMA Positron Emission Tomography (PET) Scan, Technetium Tc 99M Medronate - Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 2 | Active not recruiting | University of California, San Francisco | 2 | 2024-08-30 | 2026-01-14 |
| Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC Darolutamide, Radium-223 - Metastatic Prostate Cancer | Phase 3 | Withdrawn | GenesisCare USA | 2023-09-01 | 2023-09-14 | |
| Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland abiraterone, enzalutamide, docetaxel - Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC) | Completed | Pfizer | 1083 | 2023-02-13 | 2026-01-29 | |
| Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer Lutetium-177 PSMA-I&T, Radium-223 - Metastatic Castration-resistant Prostate Cancer, MCRPC | Phase 1 / Phase 2 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 36 | 2022-09-13 | 2025-02-07 |
| Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) radium-223, Bipolar Androgen Therapy (BAT) - Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 47 | 2022-04-28 | 2026-02-06 |
| A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones Radium dichloride, PET Scan - Prostate Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 12 | 2021-11-12 | 2026-04-28 |
| Radium-223 in Biochemically Recurrent Prostate Cancer Radium-223, 18F Sodium Fluoride - Biochemical Recurrent Prostate Cancer | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 19 | 2020-09-22 | 2026-03-16 |
| Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer Nivolumab, Radium-223 - Metastatic Castration-resistant Prostate Cancer | Phase 1 | Active not recruiting | University of Utah | 39 | 2020-09-16 | 2026-06-01 |
| RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers Radium-223, stereotactic ablative radiotherapy (SABR) - Prostate Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 64 | 2019-08-09 | 2025-12-19 |
| Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo). Radium-223 (Xofigo, BAY88-8223), Abiraterone, Enzalutamide - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Completed | Bayer | 346 | 2019-03-18 | 2021-12-29 | |
| A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223 Radium-223 (Xofigo, Bay88-8223) - Prostatic Neoplasms, Castration-Resistant | Completed | Bayer | 164 | 2018-07-31 | 2020-05-20 | |
| A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223 - Prostate Cancer | Phase 3 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 732 | 2018-06-19 | 2026-05-14 |
| Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC Dexamethasone plus Radium-223 - Metastatic Prostate Cancer | Phase 4 | Unknown | University Health Network, Toronto | 24 | 2018-02-23 | 2024-01-24 |
| Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer Docetaxel, Radium 223 - Metastatic Castrate Resistant Prostate Cancer | Phase 1 | Completed | Tufts Medical Center | 43 | 2018-01-30 | 2025-10-07 |
| Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy Atezolizumab, Radium-223 - Urothelial Carcinoma | Early Phase 1 | Terminated | University of Michigan Rogel Cancer Center | 1 | 2017-11-01 | 2018-10-24 |
| The Combination Therapy With Ra-223 and Enzalutamide Ra-223 in combination with enzalutamide - Castration-resistant Prostate Cancer, Bone Metastases | Phase 2 | Unknown | Taro Iguchi, MD, PHD | 10 | 2017-10-27 | 2021-09-09 |
| Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer Radium-223, Docetaxel - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Unknown | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 70 | 2017-09-01 | 2024-09-27 |
Showing 20 of 30. Sign in to see all of them.
Prostatic Neoplasms (20) · Neoplasm Metastasis (2) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Clear-cell metastatic renal cell carcinoma (1) · Fatigue (1) · Pain (1) · Prostatic Neoplasms, Castration-Resistant (1)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Memorial Sloan Kettering Cancer Center (3) · Bayer (2) · Dana-Farber Cancer Institute (2) · Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD (1) · Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (1) · AstraZeneca (1) · Azienda Policlinico Umberto I (1) · Cancer Trials Ireland (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · GenesisCare USA (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · MedSIR (1) · National Cancer Institute (NCI) (1) · Peter MacCallum Cancer Centre, Australia (1)
United States (16) · Spain (5) · Brazil (4) · Italy (4) · Belgium (3) · Canada (3) · France (3) · Netherlands (3) · Australia (2) · Finland (2) · Ireland (2) · Japan (2) · Poland (2) · Switzerland (2) · United Kingdom (2)
Michael Morris, MD (2) · Ajjai Alva, M.D. (1) · Ana Kiess, M.D. (1) · Ana Kiess, MD, PhD (1) · Atish Choudhury, MD (1) · Bertrand Tombal, Prof (1) · Brandon Imber, MD (1) · David Lorente, M.D., Ph.D. (1) · Emmanuel Antonarakis, MD (1) · Giuseppe De Vincentis, MD, PhD (1) · Guillermo de Velasco, M.D., Ph.D. (1) · Inge M. van Oort, MD, PhD (1) · Mark Pomerantz, MD (1) · Melissa L Abel, M.D. (1)
PMID 32487038, PMID 33451978, PMID 34636627, PMID 35027313, PMID 35804188, PMID 35981452, PMID 36465905, PMID 39827019, PMID 40334149, PMID 41119954, PMID 41313045, PMID 42221687
2016 (2), 2014 (1), 2018 (1), P01CA272222 (1)